US EditionPublished • loading... • Updated
CDI Breakthroughs Lead to New Drug Development Deal for Deadly NTM Bacteria
Summary by Newswise
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
NewswiseReposted by 
Stemwell Science News
Stemwell Science NewsCDI Breakthroughs Lead to New Drug Development Deal for Deadly NTM Bacteria
The CDI’s top NTM scientists, Véronique Dartois, Ph.D., and Thomas Dick, Ph.D., have developed new compounds which are now subject of a new collaboration and license agreement with the Switzerland-based and publicly listed BioVersys AG. As announced on March 31, the two parties will jointly profile and develop rifamycin candidates identified by HMH.
·Charlottesville, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
